Response outcomes within 6 cycles of treatment
| Outcome∗ . | Magrolimab, venetoclax, and azacitidine (n = 189) . | Placebo, venetoclax, and azacitidine (n = 189) . |
|---|---|---|
| CR rate, % (95% CI) | 41.3 (34.2-48.6) | 46.0 (38.8-53.4) |
| Stratified OR (95% CI) | 0.856 (0.560-1.307) | |
| Median duration of CR, months (95% CI) | 9.4 (6.3-NE) | 8.1 (5.7-NE) |
| Median time to CR, months (IQR) | 1.26 (0.95-2.53) | 1.87 (0.95-2.60) |
| CR without MRD rate, % (95% CI) | 21.7 (16.0-28.3) | 20.1 (14.6-26.5) |
| Stratified OR (95% CI) | 1.154 (0.690-1.932) | |
| CR + CRh rate, % (95% CI) | 47.6 (40.3-55.0) | 53.4 (46.1-60.7) |
| Stratified OR (95% CI) | 0.826 (0.545-1.251) | |
| Composite CR rate,† % (95% CI) | 67.2 (60.0-73.8) | 68.8 (61.7-75.3) |
| Outcome∗ . | Magrolimab, venetoclax, and azacitidine (n = 189) . | Placebo, venetoclax, and azacitidine (n = 189) . |
|---|---|---|
| CR rate, % (95% CI) | 41.3 (34.2-48.6) | 46.0 (38.8-53.4) |
| Stratified OR (95% CI) | 0.856 (0.560-1.307) | |
| Median duration of CR, months (95% CI) | 9.4 (6.3-NE) | 8.1 (5.7-NE) |
| Median time to CR, months (IQR) | 1.26 (0.95-2.53) | 1.87 (0.95-2.60) |
| CR without MRD rate, % (95% CI) | 21.7 (16.0-28.3) | 20.1 (14.6-26.5) |
| Stratified OR (95% CI) | 1.154 (0.690-1.932) | |
| CR + CRh rate, % (95% CI) | 47.6 (40.3-55.0) | 53.4 (46.1-60.7) |
| Stratified OR (95% CI) | 0.826 (0.545-1.251) | |
| Composite CR rate,† % (95% CI) | 67.2 (60.0-73.8) | 68.8 (61.7-75.3) |
Medians are based on Kaplan-Meier estimates. Durations of response and times to response are calculated for patients who achieved the indicated response category.
CRi, complete remission with incomplete hematologic recovery; IQR, interquartile range.
All rates are within 6 cycles of treatment and were calculated using the ITT population as the denominator.
Composite CR includes CR, CRi, or CRh.